[1P-0591] Application of the novel CRISPR-Cas3 technology for low immune rejection iPS cell therapy and Duchenne muscular dystrophy gene therapy
genome editing, CRISPR-Cas, iPSC, immune rejection, Duchenne muscular dystrophy
This archive has moved to the member page of The Molecular Biology Society of Japan.
Members can access the abstracts via links at the member page of the sites.
Please feel free to contact the journal offices for any inquiries.